Product Information
DILTIAZEM 24H ER(LA) 360 MG TB is a generic product labeled by Cipla USA Inc., priced at $1.8337 per EA under NDC 69097099602. Its NADAC has been published 157 times since Oct 4, 2023.
FDA first approved this application on Apr 6, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
360 mg/1
Manufacturer
Cipla USA Inc.NDC
69097099602
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DILTIAZEM HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA216327FDA Approved
4/6/2023
TE Code
AB
On Market Since
6/12/2023
Pharmacological Classes
Price Statistics
The NADAC for DILTIAZEM 24H ER(LA) 360 MG TB has been published 157 times since Oct 4, 2023, and over the history we have for it it has declined 38.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.8337 per EA |
|---|---|
| All-time high | $2.9914 (Oct 11, 2023) |
| All-time low | $1.8337 (Sep 23, 2026) |
| 52-week high | $2.6613 |
| 52-week low | $1.8337 |
| Median price | $2.5788 |
| Average price | $2.4792 |
| Largest weekly change | +33.4% (Jun 19, 2024) |
| Weeks tracked | 157 |
| Tracking since | Oct 4, 2023 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Cipla USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
diltiazem hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Calcium Channel Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DILTIAZEM 24H ER(LA) 360 MG TB?
The current National Average Drug Acquisition Cost (NADAC) for DILTIAZEM 24H ER(LA) 360 MG TB, manufactured by Cipla USA Inc., is $1.8337 per EA (NDC 69097099602), effective Sep 30, 2026.
How has the price of DILTIAZEM 24H ER(LA) 360 MG TB changed over time?
Over the history we have for it, the NADAC for DILTIAZEM 24H ER(LA) 360 MG TB has declined 38.7%. It has been tracked across 157 weekly CMS publications since Oct 4, 2023.
What are the highest and lowest recorded NADAC prices for DILTIAZEM 24H ER(LA) 360 MG TB?
Since Oct 4, 2023, the NADAC for DILTIAZEM 24H ER(LA) 360 MG TB has ranged from a low of $1.8337 (Sep 23, 2026) to a high of $2.9914 (Oct 11, 2023), with a median of $2.5788 per EA.
Are there cheaper alternatives to DILTIAZEM 24H ER(LA) 360 MG TB?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as DILTIAZEM 24H ER(LA) 360 MG TB in a comparable dosage form, but none are currently priced below it.
Who manufactures DILTIAZEM 24H ER(LA) 360 MG TB?
DILTIAZEM 24H ER(LA) 360 MG TB (NDC 69097099602) is labeled by Cipla USA Inc., and CMS classifies it as a generic product.